tiprankstipranks
Advertisement
Advertisement

GANX Stock Latest News

Reiterating Buy on Gain Therapeutics: Promising GT-02287 Parkinson’s Data and Diversified GCase Pipeline Support $8 Target
RatingsReiterating Buy on Gain Therapeutics: Promising GT-02287 Parkinson’s Data and Diversified GCase Pipeline Support $8 Target
11d ago
GANX
Gain Therapeutics reports Q4 EPS (61c), consensus (14c)
PremiumThe Fly
Gain Therapeutics reports Q4 EPS (61c), consensus (14c)
15d ago
GANX
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data
PremiumCompany Announcements
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data
23d ago
8K
GANX
Gain announces presentations on Phase 1b clinical study of GT-02287
PremiumThe Fly
Gain announces presentations on Phase 1b clinical study of GT-02287
23d ago
GANX
Gain Therapeutics, Inc. (GANX) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Gain Therapeutics, Inc. (GANX) Q4 Earnings Cheat Sheet
24d ago
GANX
Gain Therapeutics provides regulatory update on GT-02287
PremiumThe FlyGain Therapeutics provides regulatory update on GT-02287
29d ago
GANX
Buy Rating on Gain Therapeutics Driven by Validated Mechanism, Compelling Phase 1b Parkinson’s Data, and Attractive Risk‑Reward Despite Near‑Term Financing Needs
Premium
Ratings
Buy Rating on Gain Therapeutics Driven by Validated Mechanism, Compelling Phase 1b Parkinson’s Data, and Attractive Risk‑Reward Despite Near‑Term Financing Needs
3M ago
GANX
Maintaining Buy on Gain Therapeutics: Strong GCase Biology, Validated GluSph Biomarker, and Favorable Risk-Reward for GT-02287 in Parkinson’s Disease
Premium
Ratings
Maintaining Buy on Gain Therapeutics: Strong GCase Biology, Validated GluSph Biomarker, and Favorable Risk-Reward for GT-02287 in Parkinson’s Disease
3M ago
GANX
Gain Therapeutics provides additional data from Phase 1b study of GT-02287
PremiumThe Fly
Gain Therapeutics provides additional data from Phase 1b study of GT-02287
3M ago
GANX
Gain Therapeutics: Attractive Upside on GT-02287 Parkinson’s Data and Upcoming KOL Catalyst Supports Buy Rating
PremiumRatings
Gain Therapeutics: Attractive Upside on GT-02287 Parkinson’s Data and Upcoming KOL Catalyst Supports Buy Rating
3M ago
GANX
Gain Therapeutics holds a conference call
PremiumThe Fly
Gain Therapeutics holds a conference call
3M ago
GANX
Gain Therapeutics price target raised to $10 from $6 at Roth Capital
PremiumThe Fly
Gain Therapeutics price target raised to $10 from $6 at Roth Capital
4M ago
GANX
Clinical and Mechanistic De-Risking of GT-02287 Underpins Buy Rating on Gain Therapeutics (GANX)
PremiumRatingsClinical and Mechanistic De-Risking of GT-02287 Underpins Buy Rating on Gain Therapeutics (GANX)
4M ago
GANX
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Biomarker Data and Efficient Clinical Path Support Disease‑Modifying Potential in Parkinson’s
Premium
Ratings
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Biomarker Data and Efficient Clinical Path Support Disease‑Modifying Potential in Parkinson’s
4M ago
GANX
Gain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data
Premium
Company Announcements
Gain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data
4M ago
8K
GANX
Gain Therapeutic announces Phase 1b study of GT-02287 met prespecified endpoint
PremiumThe Fly
Gain Therapeutic announces Phase 1b study of GT-02287 met prespecified endpoint
4M ago
GANX
Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Developments and Upcoming Clinical Data
PremiumRatings
Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Developments and Upcoming Clinical Data
4M ago
GANX
Gain Therapeutics Announces New Stock Offering Program
PremiumCompany Announcements
Gain Therapeutics Announces New Stock Offering Program
4M ago
8K
GANX
Buy Rating for Gain Therapeutics: Promising Innovations in Disease Treatment
PremiumRatings
Buy Rating for Gain Therapeutics: Promising Innovations in Disease Treatment
5M ago
GANX
Gain Therapeutics presents data on GT-02287
PremiumThe FlyGain Therapeutics presents data on GT-02287
5M ago
GANX
Positive Outlook for Gain Therapeutics: Promising Clinical Trial Results and Stable Financial Health Drive Buy Rating
Premium
Ratings
Positive Outlook for Gain Therapeutics: Promising Clinical Trial Results and Stable Financial Health Drive Buy Rating
5M ago
GANX
Promising Developments in Gain Therapeutics’ Parkinson’s Treatment Drive Buy Rating
Premium
Ratings
Promising Developments in Gain Therapeutics’ Parkinson’s Treatment Drive Buy Rating
5M ago
GANX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >